1. Pink Sheet
  2. >>Geography
  3. >>Europe

Sputnik V COVID-19 Vaccine Causing A Stir In The EU

No Special Inquiry Into Clinical Trials, Says EMA

 
• By Ian Schofield

The team behind Sputnik V has attacked what it calls “fake news and provocations” in the EU as political arguments over the vaccine claim another ministerial scalp.

Sputnik 5 vaccine against COVID-19. Glass medical vials with liquid on the background Sputnik V company logo
Russia's Sputnik V is not part of the EU's COVID-19 vaccine portfolio • Source: Alamy

Amid renewed concern over COVID-19 vaccine supplies following warnings by European regulators about the risk of rare blood clots with the Oxford/AstraZeneca PLC vaccine, EU countries are increasingly eyeing up the pros and cons of using Russia’s Sputnik V. But the vaccine is at the eye of a growing political storm.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

US FDA Asks Adcomm If Opioid Postmarketing Studies Are Relevant, Warrant Action

 
• By Sue Sutter

Two US FDA advisory committees will discuss results from epidemiological studies that attempted to quantify the prevalence, incidence and risk factors for misuse, abuse, overdose and death with opioid analgesics.

Raising Drug Prices In The EU Could Take Years, Even If Pharma Effort Succeeds

 
• By Cathy Kelly

Manufacturers are engaging the European Commission and individual countries to allocate more health care spending to innovative medicines and align prices more closely to those in the US.

Non-Submissions To UK HTA Body Could Increase Unless Commercial Environment Improves, Warns Industry

 
• By Leela Barham

Finding ways to lower the rebates paid by the pharmaceutical industry to the UK government and fostering partnerships to make the UK a more attractive launch market could help reduce the number of terminated technology appraisals conducted by NICE, the health technology appraisal institute, says the UK pharmaceutical industry.